Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.20
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.20
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.28 - $1.83
Previous CloseN/A
Volume2.02M
Average Volume (3M)3.09M
Market Cap
$518.06M
Enterprise Value$526.55M
Total Cash (Recent Filing)$115.95M
Total Debt (Recent Filing)$58.15M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Mar 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding395,466,280
10 Day Avg. Volume4,493,394
30 Day Avg. Volume3,086,668
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.62
Price to Sales (P/S)7.60
P/FCF Ratio-1.31
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue7.43
Enterprise Value/Gross Profit11.78
Enterprise Value/Ebitda-10.90
Forecast
1Y Price Target
$4.03Price Target Upside235.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data Supporting Dosing And TolerabilityPhase 2b PROGRESS results that identified a once-daily dose with meaningful pain reduction, placebo-like completion rates, and a generally well-tolerated safety profile increase confidence in success for upcoming pivotal trials.
Commercial Expansion And Broader IndicationsCommercial launch of INPEFA in new markets combined with planned regulatory filings in additional countries and a diversified late-stage pipeline offer multiple avenues for new revenue beyond core regions.
Regulatory Progress For PilavapadinFavorable End-of-Phase-2 feedback and absence of unexpected study requirements from the FDA enable advancement of pilavapadin into pivotal diabetic peripheral neuropathic pain studies, supporting a clearer path toward potential registration.
Bears Say
Execution And Regulatory RiskFuture revenue and program advancement hinge on successful regulatory resubmissions and pivotal trial outcomes, exposing the stock to elevated execution risk if key milestones are delayed or unmet.
Partner DependenceCommercial and clinical progress depends on partner actions and regulatory approvals, meaning partner decisions or setbacks could materially affect commercialization timing and expected revenue.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $1.83 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $518.06M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 18, 2026 which is in 32 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.026.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 395,466,280 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.03 (235.83% Upside)
$4.03 (235.83% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 229.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.30%
12-Months-Change
Fundamentals
Return on Equity
-45.92%
Trailing 12-Months
Asset Growth
-35.87%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in revenues, R&D advancements, and strategic partnerships, while also highlighting challenges such as decreased cash reserves and the need for FDA feedback for key products. Overall, the positive aspects of the company's progress and strategic focus on future opportunities suggest a cautiously optimistic outlook.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$4.03
▲(235.83% Upside)
Technical Analysis
Ownership Overview
13.05% Insiders
8.74% Mutual Funds
0.26% Other Institutional Investors
75.25% Public Companies and
Individual Investors